Prime editing advances toward in vivo genetic disease treatments
This digest was compiled by AI from multiple sources — links to the originals are below.
Scientists have improved nearly every aspect of prime editing, a gene-editing technology that can potentially repair the vast majority of known disease-causing human mutations. The advances move the technique closer to being used directly in the body to treat genetic diseases, rather than only on cells outside the body.
The Technology
Prime editing, first developed in 2019, can potentially repair the vast majority of known disease-causing human mutations. However, it has not yet been widely used in vivo to treat genetic disease. The only clinical application announced so far uses the technology to edit cells outside the body before transplanting them back into the patient.
Recent Improvements
Researchers have made significant improvements to prime editing, enhancing its efficiency, precision, and delivery. These advances address key limitations that previously hindered in vivo applications. The improvements bring the technology closer to clinical use for a wide range of genetic disorders.
What's Next
The next step is to test the improved prime editing system in animal models and eventually in human clinical trials. It remains unclear how soon the technology will be ready for widespread therapeutic use in the body.
1 source
Prime editing advances toward in vivo genetic disease treatments
